This 35 year old man was suffering from seborrheic dermatitis. I gave him Crisaborole (Eucrisa)2% ointment and instructed him to apply twice daily, especially after showering. He reported a mild tingling the first few days, but not significant enough to keep him from adhering to the treatment plan. Here he is 7 days later. He was happy with the results and I instructed him to employ pulse therapy (use once or twice per week) for maintenance, and repeat the BID protocol for 5-7 days for any future flare-ups or break-throughs.

Crisaborole is a phosphodiesterase-4 inhibitor, mainly acting on phosphodiesterase 4B (PDE4B), which causes inflammation. Chemically, crisaborole is a phenoxybenoxaborole. It contains a boron atom that helps penetrate the skin and is essential for its binding activity. Inhibition of PDE4B appears to suppress the release of tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), IL-23 and other cytokines, proteins believed to be involved in the immune response and inflammation. Crisaborole is also being investigated for the treatment of psoriasis. (Wikipedia)

In December of 2016, Crisaborole was FDA approved for the treatment of atopic eczema in children 2 years and older.

In this case, Crisaborole serves as an effective, non-steroidal treatment, like the macrolactam agents (e.g. pimecrolimus and tacrolimus) for the chronic condition, seborrheic dermatitis.

(I have NO financial interests in Crisaborole or its manufacturer.)

Reference:
Pimecrolimus: A New Treatment for Seborrheic Dermatitis, Cutis. 2002 October;70(4):207-208. Crutchfield III, C.E.)